Suchergebnisse
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February
Capricor Therapeutics CAPR recently provided a regulatory update on its Biologics License Application (BLA) for Deramiocel, following recent interactions with the FDA. After reviewing topline data
